Media headlines about Boston Scientific (NYSE:BSX) have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Boston Scientific earned a coverage optimism score of 0.19 on Accern’s scale. Accern also assigned news coverage about the medical equipment provider an impact score of 46.7957696804256 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the news articles that may have effected Accern Sentiment’s rankings:
- Global Escitalopram Market Study 2018- Boston Scientific Corporation , EndoChoice, Inc. , Conmed Corporation , Cook … (expressobserver.com)
- Global Flexible Endoscopy Equipment Market Analysis 2018 – Ethicon, Boston Scientific Corporation and Olympus … (theperfectinvestor.com)
- Global Urinary Catheters Market Share 2018: CR Bard Inc., Boston Scientific Corporation, Convatec Group PLC … (thefreenewsman.com)
- Global Calcium Electrode Market Study 2018- Ambu Inc , Boston Scientific Corporation , Cogentix Medical (cherrygrrl.com)
- Global Surgical Lasers Market Share 2018: Abbott Laboratories Inc., Lumenis, Boston Scientific Corporation, Alma … (truthfulobserver.com)
A number of research firms have issued reports on BSX. Raymond James boosted their price target on Boston Scientific from $32.00 to $34.00 and gave the company a “strong-buy” rating in a research report on Thursday, April 26th. Zacks Investment Research raised Boston Scientific from a “hold” rating to a “buy” rating and set a $34.00 price target for the company in a research report on Friday, May 11th. TheStreet downgraded Boston Scientific from a “b” rating to a “c” rating in a research report on Monday, March 5th. Canaccord Genuity reissued a “buy” rating and set a $36.00 price target on shares of Boston Scientific in a research report on Wednesday, April 25th. Finally, ValuEngine raised Boston Scientific from a “hold” rating to a “buy” rating in a research report on Monday, June 11th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, seventeen have given a buy rating and three have assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $32.45.
Shares of Boston Scientific opened at $32.62 on Friday, according to MarketBeat.com. Boston Scientific has a 1-year low of $24.54 and a 1-year high of $37.30. The company has a quick ratio of 0.59, a current ratio of 0.82 and a debt-to-equity ratio of 0.68. The stock has a market capitalization of $44.36 billion, a PE ratio of 25.89, a P/E/G ratio of 2.29 and a beta of 0.77.
Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, April 25th. The medical equipment provider reported $0.33 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.32 by $0.01. Boston Scientific had a return on equity of 25.10% and a net margin of 1.21%. The business had revenue of $2.38 billion for the quarter, compared to analysts’ expectations of $2.34 billion. During the same quarter in the previous year, the firm posted $0.29 earnings per share. The company’s revenue was up 10.1% compared to the same quarter last year. research analysts anticipate that Boston Scientific will post 1.39 EPS for the current fiscal year.
In related news, EVP David A. Pierce sold 5,000 shares of the business’s stock in a transaction dated Monday, April 2nd. The stock was sold at an average price of $27.22, for a total value of $136,100.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Jeffrey B. Mirviss sold 19,323 shares of the business’s stock in a transaction dated Thursday, June 14th. The stock was sold at an average price of $32.64, for a total value of $630,702.72. The disclosure for this sale can be found here. In the last quarter, insiders sold 163,030 shares of company stock worth $5,211,897. Insiders own 0.73% of the company’s stock.
Boston Scientific Company Profile
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.